H
ospitalizations for exacerbations of chronic obstructive pulmonary disease (COPD) are associated with decreases in health-related quality of life, lung function, and life expectancy and account for more than half of all COPD-related medical costs (1) (2) (3) (4) (5) . Successful efforts to reduce COPD hospitalization rates would yield important human and economic benefits.
Implementation of comprehensive care management programs (CCMPs) is generally associated with improved patient satisfaction; adherence; and disease control in patients with depression, diabetes, arthritis, and congestive heart failure (6 -8) . Trials of care management in COPD are few in number and highly variable in terms of patients, interventions, outcomes, duration of follow-up, and quality (9 -13). Most previous interventions did not describe the underlying health behavioral theory or health communication model anticipated to change specific patient behaviors that improve clinical outcomes. Most systematic reviews have concluded that care management programs probably reduce overall health care use, but the reduction in COPD hospitalizations has not been consistent and was not shown in the largest trial reported to date (13) (14) (15) (16) (17) .
In this study, we hypothesized that a theory-based CCMP that included COPD education, an individualized treatment action plan for worsening pulmonary symptoms, and telephone case management would reduce the risk for COPD-related hospitalization in patients with severe COPD who were at high risk for hospital admission.
METHODS

Design Overview
We conducted a multisite, randomized, controlled trial comparing a CCMP with guideline-based usual care for patients with COPD who were at high risk for hospitalization.
Setting and Patients
Patients in the study had been hospitalized for COPD in the 12 months before enrollment. Additional inclusion criteria were a postbronchodilator ratio of FEV 1 to FVC below 0.70 with an FEV 1 below 80% predicted, age older than 40 years, current or past history of cigarette smoking (Ͼ10 pack-years), at least 1 visit in the past year to either a primary care or pulmonary clinic at a Veterans Affairs (VA) medical center, no COPD exacerbation in the past 4 weeks, ability to speak English, and access to a telephone. Patients were excluded for a primary diagnosis of asthma or any medical conditions that would impair their ability to participate in the study or to provide informed consent. The trial commenced with 6 sites in January 2007 and subsequently expanded to 20 sites.
The institutional review boards at all sites approved the study, and all patients gave written informed consent. In accordance with VA Cooperative Studies Program (CSP) procedures, the ethical and scientific aspects of the study were evaluated by the CSP Human Rights Committee. A Data and Safety Monitoring Committee (DMC) reviewed the study at least annually.
Randomization and Interventions
The CSP Coordinating Center in Boston, Massachusetts, randomly assigned eligible patients in equal numbers to 2 groups, stratifying patients by site to allow for possible regional differences in patient characteristics and clinical practice patterns. Randomization lists were generated on the basis of random, permuted blocks of variable size to ensure approximate balance over time.
The 2 groups differed on the basis of a complex behavioral intervention that made blinding impossible. Telephone-based ascertainment of study outcomes (COPD hospitalizations and exacerbations) was performed by centralized research staff blinded to assignment.
CCMP Intervention
The educational intervention was based on the PRECEDE/ PROCEED model of health program planning and evaluation (18) . Interventions developed with this model address the key predisposing, reinforcing, and enabling factors that influence health behaviors. We identified key environmental and behavioral factors from prior studies and clinical experience that might contribute to exacerbations of COPD, and we focused on those most likely to have an effect and to be adopted by patients. The educational program consisted of 4 individual 90-minute weekly sessions. The sessions used an educational booklet developed specifically for this study (19) . Topics and educational objectives were a needs assessment followed by an overview of COPD, including medications and exacerbations; self-monitoring of respiratory symptoms and instructions for self-initiation of an antibiotic or prednisone for an exacerbation; learning breathing and coughing techniques and strategies for energy conservation and reduction of anxiety; and medication adherence, smoking cessation, nutrition, and regular exercise at home. The individual lessons were reinforced during a group session and by telephone calls from the case manager once per month for 3 months and every 3 months thereafter.
Intervention patients received a written, individualized action plan for flare-ups that included prescriptions for prednisone and an antibiotic (chosen in consultation with
Context
Educational and management programs in which patients are provided with prescriptions and instructions for actions to initiate at the onset of worsening symptoms have been reported in some studies to reduce hospitalizations for acute exacerbations of chronic obstructive pulmonary disease (COPD).
Contribution
This multisite, randomized, controlled trial of an educational and acute care management program was stopped early when a safety monitoring board noted more deaths in the intervention group. There was no difference seen in the number of hospitalizations or the time to initiation of treatment for an acute COPD exacerbation.
Caution
The cause of the increased mortality and the reason that intervention patients did not initiate treatment sooner could not be identified with available data.
Implication
Not all educational and care management programs are appropriate for all patients. Safety monitoring boards are important for educational and behavioral intervention studies.
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Original Research Comprehensive Care Management Program to Prevent COPD Hospitalizations the primary care physician) with instructions to initiate treatment within 48 hours after onset of exacerbation symptoms. On the basis of change in patient symptoms, the written action plan specified whether the patient should start an antibiotic or prednisone (Supplement 1, available at www.annals.org). At the beginning of the study, intervention patients were provided with prescriptions that they were expected to fill and refill as needed to always have medications on hand in case of an exacerbation. Patients were also asked to call their case manager after initiating their action plan and their primary care provider or 911 if symptoms worsened or failed to respond to treatment. Case managers were instructed to contact the patient's primary care provider if an exacerbation occurred. Case managers were also available by telephone during regular work hours to answer questions about the action plan.
With the exception of 2 study coordinators, case management positions were filled by various health-related professionals (Appendix Table 1 , available at www.annals .org). At any point, each site had only 1 case manager who taught the educational sessions and made proactive case management telephone calls. Before starting the study, all case managers received a 3-day training course with workshops covering detailed aspects of the self-management program, and all were supervised by the site investigator. Quality of and adherence to the educational program were monitored by recording and reviewing 1 of every 4 COPD educational sessions for each patient. Each audio recording was reviewed by a research assistant who completed a checklist to determine the proportion of educational elements that were covered by the case manager. The maximum possible scores for recorded sessions 1 through 4 were 31, 19, 17, and 23, respectively.
Guideline-Based Usual Care
Primary care providers for patients in both groups received the Global Initiative for Chronic Obstructive Lung Disease guidelines and were advised to manage their patients according to published guidelines (20 -22). All participants received a general information booklet for patients with COPD and had access to an existing VA 24-hour help line for any medical questions about their COPD.
Outcomes and Follow-up
The primary outcome was time from randomization to first COPD hospitalization. The goal was to follow all patients for at least 12 months. Research staff blinded to study group contacted patients every 2 months to determine whether they developed symptoms of a COPD exacerbation, along with details of treatment and health care use. A COPD exacerbation was defined as an increase in or new onset of 1 or more respiratory symptoms (cough, sputum, wheezing, dyspnea, or chest tightness) persisting for at least 2 days.
Per protocol, 3 blinded pulmonologists reviewed discharge summaries and other available information to determine the primary cause of all hospitalizations and classified them as COPD-related (exacerbation or pneumonia), cardiovascular, or other.
Secondary outcomes included all-cause mortality, number of exacerbations, health-related quality of life, patient satisfaction, COPD-related knowledge, and self-efficacy.
Baseline and Follow-up Assessments
At baseline and 1-year study visits, we performed postbronchodilator spirometry according to American Thoracic Society criteria and collected medical and sociodemographic data (23). Disease-specific health-related quality of life was measured with the St. George's Respiratory Questionnaire (24) , which has 76 questions that can be summarized in 3 subscales (symptoms, activity, and impacts), each with a score ranging from 0 (best) to 100 (worst); the minimum clinically important difference is 4. General health-related quality of life was measured with the Veterans Medical Outcomes Study Short Form-12 (25, 26) , which has 12 questions summarized in 2 subscales (physical and mental component summary scales); scores range from 0 (worst) to 100 (best) (27) . We measured depressive symptoms with the 8-item Patient Health Questionnaire, the score of which ranges from 0 (no depressive symptoms) to 24; a score of 10 or higher indicates depression (28) . Patient satisfaction was measured with the Seattle Outpatient Satisfaction Questionnaire, which has 21 questions that are summarized in 2 subscales (humanistic and organizational) and a scoring range of 0 (least satisfied) to 100 (most satisfied) (29) . A 15-item COPD knowledge questionnaire assessed medication use, management of dyspnea, and exacerbations (Supplement 2, available at www.annals .org). We developed an 8-item questionnaire to measure patients' self-efficacy in carrying out the targeted selfmanagement behavior (30, 31) (Supplement 3, available at www.annals.org).
Statistical Analysis
The outcome for the primary analysis was time to event for a first COPD hospitalization. We based the sample size on the test of the primary hypothesis with 90% power to reject the null hypothesis for the log-rank test, based on enrolling 960 patients and losing 7% annually and assuming a hazard ratio (HR) of 1.37 (or 0.73). No interim analyses were planned. The study began with 6 sites to determine whether recruitment goals could be met. After this was achieved, the study was expanded to the full 20 sites.
For the primary intention-to-treat analysis, the null hypothesis was that the COPD hospitalization hazard rate for intervention did not differ from that for standardized care. The log-rank test had a 2-sided alternative hypothesis that the ratio of the 2 hazard rates was either greater than 1.37 or less than 0.73 (1/1.37). The direction of interest was whether treatment reduced the hospitalization rate by 8% annually. This assumes underlying exponential failure rates and a 30% annual hospitalization rate for the control group, consistent with COPD data from the VA. Results in the opposite direction were regarded as negative results. The primary analysis had no covariates. The estimated HR comparing treatments was obtained from the Cox proportional hazards model analogous to the log-rank test (32) . One-year rates of COPD hospitalization-free survival were obtained by the Kaplan-Meier method. Planned exploratory analyses used the Cox proportional hazards model to indicate whether covariates could account for some of the treatment effect.
The early termination led to several unplanned post hoc analyses focusing on the use of prednisone and antibiotics. As might be expected, previous studies with similar interventions have found increased use of medications to treat exacerbations (9, 13) . We compared the annual rates of prednisone and antibiotic treatment for exacerbations in each group by using data from the first year of follow-up. Because some patients had shorter follow-up times, we computed the rates as the number of times the medication was taken divided by the total patient-years. We compared the number of exacerbation episodes requiring prednisone and antibiotic use across treatments by using a repeatedmeasures, unadjusted Poisson model with the generalized estimating equation method for the number of episodes over time per person. The model provided an estimate of the ratio of the Poisson rates. Also, the number of days from onset of an episode to first use of prednisone or an antibiotic was compared across treatments by using a mixed-effects model with a single fixed covariate for treatment. We compared the number of days over time per patient, assuming that each patient's series of monthly exacerbation counts were autocorrelated (first-order structure) and weighting the data according to each patient's time in the study if less than 1 year.
The early termination also led to further Cox model analyses of time to death. Appendix Table 2 (available at www.annals.org) describes various models used to detect the role of the categorical factor "study site" on time to death. Also, with respect to time to first COPD hospitalization, we conducted a futility analysis to assess what might have resulted if the trial had continued. We computed the probability of rejecting the null hypothesis conditional on the data accrued when enrollment stopped. Under the alternative hypothesis (HR, 1/1.37 ϭ 0.73; log[HR], Ϫ0.315), we approximated the probability that future data acquired up to the planned termination would have led to rejection of the null hypothesis. We assumed that the logarithm of the HR was normally distributed with variance 4/m, where "m" was the accrued number of events (33, 34) .
Significance levels for exploratory analyses were set at 5% for all tests without correction for multiple comparisons. We used the log-rank test, Kaplan-Meier estimates, and Cox analysis for the time-to-event analyses. We performed all analyses by using SAS, version 9.2 (SAS Institute, Cary, North Carolina).
Data and Safety Monitoring
In contrast to behavioral clinical trials in studies funded by the National Institutes of Health, for which a safety officer is typically sufficient, a DMC is required for all VA CSP trials regardless of the nature of the intervention. Because the action plan included self-initiated prednisone and antibiotics, the trial's executive committee (Appendix, available at www.annals.org) supported having a DMC. The DMC monitored patient accrual, outcomes, complications, and protocol adherence. Summary minutes of the proceedings were kept confidential, and decisions were made during the executive section of the DMC meeting without investigators present. As the study sponsor, the VA CSP received recommendations from the DMC. Every 6 months, the study biostatistician provided the DMC with reports on the study status and presented data blinded to treatment assignment.
Role of the Source of Funding
The VA CSP provided guidelines for the overall management and conduct of the study. 
RESULTS
The study began enrollment in January 2007. At a scheduled DMC meeting on 15 January 2009, the report showed an imbalance in mortality between the 2 study groups. The DMC requested a log-rank test to compare the time-to-event rates, and this showed a statistically significant difference. The DMC then requested a more complete analysis.
Deaths were ascertained by staff at the study sites, by review of VA electronic medical and administrative records and by a search of the Social Security Death Index. Extensive multivariate analyses failed to identify any factors alone or combined that could plausibly explain the difference in mortality. Two of the authors who were blinded to study group reviewed all available medical information and did not find anything in the deaths that would not be expected in frail patients with COPD.
On 27 February 2009, the DMC reviewed these analyses and additional data and found no obvious reason for the discrepancy in mortality. The DMC recommended that study enrollment and the intervention be stopped immediately and that all patients have all baseline studies repeated and be followed in an observational study lasting 6 months. When the intervention was stopped, the investigators were told only that there was a discrepancy in serious adverse events because of a concern that unmasking the study results might bias the assessment of the follow-up procedures. Patients were also told that the intervention had been stopped because of serious adverse events. We reobtained consent from patients who returned for the final study visit recommended by the DMC because of the change in study procedure.
Findings
When the study was stopped, 467 patients had been screened and 426 enrolled (217 in the usual care group and 209 in the intervention group), with a mean follow-up of 250 days (Figure 1) . The baseline characteristics of the patients in the 2 groups are presented in Table 1 . We present results both up to the termination date of the intervention and during the additional 6 months of followup. During the entire follow-up period extending to September 2009, a total of 8 patients in the intervention group and 10 in the usual care group either did not attend scheduled study visits or formally withdrew from the study.
Among patients in the intervention group, 87% completed all 4 individual educational visits and 57% completed the group visit. A review of the recorded sessions found that case managers covered 77% to 89% of the educational items in each session. The ranges of average scores across sites that provided audio recordings for each session were 18.3 to 31 for session 1 (13 sites), 12 to 19 for session 2 (12 sites), 12.7 to 23 for session 3 (10 sites), and 6 to 18 for session 4 (10 sites). There was no statistically significant difference in the average score for each session by site. Case managers completed 89% of the 6 scheduled reinforcement telephone calls during the first year of follow-up. In addition, 26% of all intervention group patients made at least 1 unscheduled call during the first year.
Hospitalizations
Through 1 March 2009, when the intervention was stopped, 70 patients had the primary outcome of a COPD-related hospitalization (Figure 2 and Table 2 ). At that time, the 1-year cumulative incidence of COPDrelated hospitalization was 27% in the intervention group and 24% in the usual care group (HR, 1.13 [95% CI, 0.70 to 1.80]; P ϭ 0.62). The assumption of proportional hazards was not rejected, indicating a good fit of the model to the data. Differences between treatment groups in the subtypes of COPD-related hospitalizations, in cardiovascular hospitalizations, or in all-cause hospitalizations were also not statistically significant. Inclusion of the categorical variable "study site" did not alter the results.
To predict what the result would have been if the trial had continued, we computed the probability of rejecting the null hypothesis conditional on the accrued data of 109 events when enrollment stopped (35) . Under the alternative hypothesis (HR, 1/1.37 ϭ 0.73; log[HR], Ϫ0.315), the probability that future data acquired up to the planned termination would have led to rejection of the null hypothesis was 0.0002. In other words, if a futility analysis had been planned, this result would have ended the study.
Treatment of COPD Exacerbations
During the first 12 months of follow-up, 600 selfreported COPD exacerbations occurred in the intervention group (mean, 4.4 per patient-year) and 610 in the control group (mean, 4.3 per patient-year) (rate ratio, 1.03 [CI, 0.97 to 1.10]) ( Table 3; Appendix Tables 3 and 4 , available at www.annals.org). An average of 2.5 exacerbations per patient-year were treated with prednisone in the intervention group compared with 2.1 in the usual care group (rate ratio, 1.25 [CI, 1.05 to 1.48]; P ϭ 0.011). From onset of symptoms, the average delay to prednisone treatment was 6.4 days in the intervention group and 7.7 days in the usual care group (mean difference, Ϫ0.57 day [CI, Ϫ2.14 to 1.00 days]; P ϭ 0.48). In the intervention group, an average of 2.7 exacerbations per patient-year were treated with an antibiotic compared with 2.5 in the usual care group (rate ratio, 1.11 [CI, 0.97 to 1.27]; P ϭ 0.118). The average delay to antibiotic treatment was 7.0 days in the intervention group and 6.8 days in the usual care group (mean difference, 0.17 day [CI, Ϫ1.34 to 1.68 days]; P ϭ 0.84). Data on emergency department visits are presented in Appendix Table 5 (available at www.annals.org).
Mortality
We made concerted efforts to collect information about the circumstances of all deaths. At the conclusion of the follow-up period, site coordinators at the 2 largest recruiting sites interviewed family members of deceased patients. In addition, after institutional review board approval, a research coordinator from a central site attempted to interview relatives and acquaintances of all deceased patients with the aid of a scripted questionnaire. We also sought additional medical records on all deaths regardless of group assignment.
We speculated that the educational group might have used the antibiotic regimen differently or delayed seeking attention because self-treatment may have provided a false sense of security, causing a delay in seeking care for a COPD exacerbation or such comorbid conditions as heart failure. We focused on documenting details of the patient's course and medication use in the days before death in the home or before hospital admission. Four members of the trial's Executive Committee, who were blinded to study group, independently reviewed medical records and adjudicated the cause of death as being COPD-related, cardiovascular, other, or unknown.
Information was sufficient to make a judgment about primary cause in 27 deaths or 71% of all deaths during the intervention period. With few exceptions, we were unsuccessful in obtaining detailed information about antibiotic and prednisone use immediately before death or the duration of Original Research Comprehensive Care Management Program to Prevent COPD Hospitalizations symptoms before death or hospitalization. Reasons included an inability to reach a contact person, substantial delay (sometimes as much as 2 years) between date of death and followup, and patients living alone and having only intermittent contact with friends and relatives. Medical records rarely mentioned any specific medications taken before hospital admission. When the study was terminated, 28 patients in the intervention group and 10 in the usual care group had died (HR, 3.00 [CI, 1.46 to 6.17]; P ϭ 0.003) (Figure 2 and Table 4 ). Three of these deaths were due to COPD in the usual care group compared with 10 in the intervention group, a statistically nonsignificant difference (HR, 3.60 [CI, 0.99 to 13 .08]; P ϭ 0.053) (Appendix Tables 6 and 7, available at www.annals.org, provide further details of deaths). During the 6-month follow-up, 11 deaths occurred in the usual care group (3 due to COPD) and 15 in the intervention group (4 due to COPD).
In exploratory Cox model analyses, each baseline factor was tested 1 at a time in separate models, and none markedly altered the treatment effect. In other words, no baseline factor (including site) seemed to account for the magnitude of the treatment effect. Results were consistent after adjustment for baseline factors, including age, percentage of predicted FEV 1 , current smoking status, home oxygen use, COPD-specific health-related quality of life as measured by the St. George's Respiratory Questionnaire, multiple hospitalizations, any cardiovascular disease, and congestive heart failure (adjusted HR, 2.68 [CI, 1.29 to 5.60]). In particular, 3 exploratory Cox proportional hazards models were run, 2 treating the categorical factor "study site" (the variable that partitions the data for the sandwich estimator) as a fixed effect and 1 as a random effect. The HRs for the primary analysis and these 3 models ranged from 3.00 to 3.03 (Appendix Table 2 ).
Health Status, Depression, COPD-Related Knowledge, Self-Efficacy, and Patient Satisfaction
Among the 209 patients who completed the baseline and 1-year study visits, there were no statistically significant improvements in COPD-specific or general health status, depressive symptoms, COPD-related knowledge, or patient satisfaction (Appendix Table 8 , available at www .annals.org). A statistically significant improvement was observed in patient self-efficacy (that is, self-confidence in managing COPD) in the intervention group at 1 year (mean difference of 1-year change in self-efficacy score, 0.65 [SD, 2.3] [CI, 0.02 to 1.29]; P ϭ 0.044).
DISCUSSION
In this multisite, randomized, controlled trial, we were unable to show that a theory-based CCMP reduced COPD-related hospitalizations. Based on the futility analysis, it is unlikely that a benefit would have been seen in COPD hospitalizations if the trial had continued to its planned completion. The trial was stopped because all- COPD ϭ chronic obstructive pulmonary disease; P(hosp) ϭ product-limit estimate of hospitalization at 1 y based on treating each category in isolation as opposed to competing risks. * Log-rank test P value. cause mortality was higher in the intervention group than in the usual care group. We could not demonstrate an improvement in COPD knowledge. There was a modest statistically significant difference in the rate of use of prednisone per exacerbation, but not of antibiotics, and the differences in the timing of either prednisone or antibiotic use were not statistically significant. Our findings differ from 2 previous trials that evaluated similar interventions in similar COPD populations. At 7 hospitals in Quebec, Canada, Bourbeau and colleagues (9) conducted a randomized trial of a CCMP in 181 patients with COPD, all of whom had been hospitalized in the previous year. The intervention included 7 to 8 weekly educational sessions in the patient's home, an action plan, and a case manager who made monthly calls for a year. During the 1-year follow-up, they found a 40% reduction in COPD hospitalizations in the intervention group, with 9 (9.5%) deaths in the usual care group and 5 (5.2%) deaths in the intervention group.
Rice and colleagues (13) evaluated a CCMP in 743 patients with COPD at 5 VA medical centers in 1 administrative region. Eligibility included a COPD-related hospital admission or emergency department visit, prednisone use for COPD in the previous year, or current home oxygen use. As with the Bourbeau trial, the intervention included an action plan and a case manager who made monthly telephone calls for a year. The intervention differed principally in that the initial educational program was condensed to a single 1-to 1.5-hour on-site session. The investigators found a 41% reduction in the composite primary outcome of COPD-related hospitalizations or emergency department visits in the intervention group over 1 year but a statistically nonsignificant reduction in hospitalization. Forty-eight (12.9%) deaths occurred in the usual care group versus 36 (9.7%) in the intervention group.
Aside from chance, attempts to explain the divergent results in our trial should consider characteristics of the patients or the intervention. Comparison of published baseline characteristics among these 3 trials provides no obvious clues, but subtle differences cannot be excluded.
The interventions in the 3 trials were similar but varied considerably in the intensity of the initial educational program. This would seem not to be an important factor, because the number of sessions in our trial fell midway between those of the Bourbeau trial and those of the Rice trial. Our educational program was shorter than that of the Bourbeau trial; was done at the hospital rather than at home; and was less focused on such patient behaviors as smoking cessation, diet, and exercise. The intervention in the Rice trial was shorter than in our trial, was conducted in a group setting, and focused mostly on the action plan. One potentially important difference may have been the number of reinforcement telephone calls from case managers; these were scheduled monthly for 1 year in the Bourbeau and Rice trials, whereas in our study calls were made on a monthly basis only for the first 3 months and every 3 months thereafter.
An action plan has been identified as a critical element for improving symptom recovery and reducing hospitalizations in COPD self-management programs (36, 37). Observational studies show that patients with COPD do not seek medical care for most exacerbations, that delays of up to a week after onset of symptoms are not uncommon when they do seek care, and that delays in seeking care are associated with worse clinical outcomes (38 -42) . We hoped that successful implementation of an action plan would lead to a substantial increase in the use of antibiotics and prednisone and less delay in initiating treatment.
In our study, prednisone use increased modestly in the intervention group during exacerbations (9%). There were no statistically significant differences in antibiotic use. In contrast, in Rice and colleagues' successful trial, prednisone use and antibiotic use in the intervention group increased by 262% and 191%, respectively (13) . Although patients in the intervention group were instructed to start treatment within 48 hours of worsening symptoms, we observed that treatment was begun approximately 1 week after onset of symptoms in the intervention group, similar to control patients. Although test scores for self-efficacy improved in the intervention group compared with the control group, there was no sustained improvement in COPD-related COPD ϭ chronic obstructive pulmonary disease; P(death) ϭ cause-specific product-limit estimate of death at 1 y based on treating each reason in isolation as opposed to competing risks. * Log-rank test P value. † Other causes of death in the usual care group were lung cancer (n ϭ 1) and cholangitis (n ϭ 1). Other causes of death in the intervention group were liver failure (n ϭ 1), colitis (n ϭ 2), diabetes mellitus (n ϭ 2), and trauma (n ϭ 2).
Original Research Comprehensive Care Management Program to Prevent COPD Hospitalizations knowledge. It is believed that behavior change requires both a sufficient understanding of the problem and the self-confidence to address it effectively, but our data suggest that the 2 factors are not dependent on one another. We cannot explain the unexpected increase in mortality observed in the intervention group, but we believe that the threats to internal validity, such as biased group assignment or biased outcome assessment, were not contributors. Patients were randomly allocated to study group, all outcomes were collected by centralized staff blinded to study group, and all hospitalizations were adjudicated by a committee that was also blinded to study group. Nearly all patients in the intervention group completed the individual educational sessions. Chance, imbalance between the 2 groups in unmeasured confounding factors, the effect of the intervention itself, or a combination of these are possible explanations for the between-group difference in mortality.
Efforts to deconstruct the causes and circumstances of individual deaths by examination of the medical documents were successful for only 71% of the cases during the intervention period. Excess deaths in the intervention group involved several causes ( Table 4 and Appendix Table 6), with COPD accounting for the largest difference: 10 deaths in the intervention group versus 3 in the usual care group (HR, 3.60 [CI, 0.99 to 13.08]). Inability to determine a specific cause of death in a high proportion of cases, possible misclassification of death by the adjudication procedure, and the complex intervention make it difficult to clearly delineate potential explanations for the study's observations. Severe acute exacerbations of chronic COPD are life-threatening, and the 1-year mortality rate is 21% from date of discharge from a VA hospital (43) . The overall mortality in our study is consistent with what might be expected in the general population of veterans with COPD discharged from hospitalization after a flare-up.
Examining baseline measures of COPD severity or comorbid conditions did not provide any insight into the increased risk for death. Cardiovascular diseases and unmarried status were more common in the intervention group; however, we do not know whether these factors were sufficiently important to explain the increased risk for mortality. Previously, we addressed the possibility of delays in seeking medical attention among those in the intervention group. Comparing these factors across CCMP study populations may help provide further insight into any differences.
Some limitations require discussion. The conclusions may not be generalizable to other populations because our patients were predominantly male and followed in VA medical centers. Our patients may differ from those recruited to previous studies; however, major differences are not evident from published baseline characteristics, and our patients came from diverse backgrounds at 20 sites. Although we checked the completeness of the educational elements, we were not able to scrutinize their accuracy or assess the manner in which they were delivered, which may have contributed to the study findings.
This study underscores the critical role of the DMC in ensuring the safety of study patients and questioning current clinical trial practices. Its function in terminating studies, particularly when unexpected and often unexplained adverse events occur, is one of the most vexing judgments in the conduct of trials and must be done in an environment that maintains scientific integrity and safety at its core. Currently, DMCs are not typically convened for behavioral and educational intervention studies because of the small overall perceived risk. Studies often involve only a safety officer without planned interim reports. The mortality signal was observed in a scheduled meeting that followed VA CSP standard operating procedures and would have been missed if the monitoring had not occurred routinely. Regardless of the cause of the disparity, the outcomes suggest that it should not be assumed that there are minimal safety concerns in behavioral or educational interventions.
In summary, a randomized clinical trial of the effectiveness of a CCMP in reducing hospitalizations in patients with severe COPD was terminated by its DMC before completion and was inconclusive. The self-management intervention failed to yield a structural behavioral change, in that patients in the intervention group did not initiate their action plan for worsening respiratory symptoms any sooner than the patients in the control group, as was intended. The intervention group had an unexpected excess mortality that we could not satisfactorily explain, even with additional data collection. Whatever the reason, our findings suggest that self-management or intensive management protocols may not be appropriate for all subsets of patients with COPD. and Dennis E. Niewoehner, MD, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. 
